| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On Friday, Cathie Wood-led Ark Invest made significant trades in the market, with the most prominent ones being in Veracyte Inc. (NASDAQ:VCYT), Iridium Communications Inc. (NASDAQ:IRDM), CRISPR Therapeutics AG (NASDAQ:CRSP), Kratos Defense & Security Solutions Inc. (NASDAQ:KTOS), Absci Corp. (NASDAQ:ABSI), Veeva Systems Inc. (NYSE:VEEV), Adaptive Biotechnologies Corp. (NASDAQ:ADPT) and Guardant Health Inc. (NASDAQ:GH).
The ABSI Trade
Ark’s ARK Genomic Revolution ETF (BATS:ARKG) bought a whopping 2,248,226 shares of Absci Corp, a drug discovery and development company.
The VCYT Trade
Ark Invest’s ARK Innovation ETF (BATS:ARKK) purchased 262,141 shares of Veracyte Inc., a leading genomic diagnostics company. This move aligns with Ark’s focus on disruptive innovation in the healthcare sector.
The IRDM Trade
Iridium Communications Inc., a company that provides satellite communications worldwide, saw a significant investment from Ark. The ARK Autonomous Technology & Robotics ETF (BATS:ARKQ) and ARKK bought a combined total of 66,763 shares.
The CRSP Trade
Ark Invest sold 249,108 shares of CRISPR Therapeutics AG across the ARKG and ARKK ETFs.
The KTOS Trade
Ark’s ARKQ and ARK Space Exploration & Innovation ETF (BATS:ARKX) sold 36,628 shares of Kratos Defense and Security Solutions Inc., a leading provider of unmanned systems, satellite communications, and warfighter solutions.
Other Key Trades:
Read Next:
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Posted In: ABSI ADPT ARKG ARKK ARKQ ARKX CRSP GH IRDM KTOS VCYT VEEV
